Real-time baseline coagulation profiles using ROTEM in patients undergoing liver transplantation by Del Prato, Paul & Yoon, MD, Uzung
Thomas Jefferson University 
Jefferson Digital Commons 
Phase 1 Class of 2023 
2-2021 
Real-time baseline coagulation profiles using ROTEM in patients 
undergoing liver transplantation 
Paul Del Prato 
Uzung Yoon, MD 
Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2023_phase1 
 Part of the Translational Medical Research Commons 
Let us know how access to this document benefits you 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more 
information, please contact: JeffersonDigitalCommons@jefferson.edu. 
Real-time baseline coagulation 
profiles using ROTEM in patients 
undergoing liver transplantation
Paul DelPrato, Uzung Yoon, MD*
Introduction & Objectives
• Rotational thromboelastometry (ROTEM) 
is a real-time monitoring system of 
whole blood hemostasis
• Measurements acquired can be 
considered superior to lab-based tests 
such as aPTT and PT/INR (Theusinger, et 
al. 2013)
• Long-term objective is to increase 
utilization of ROTEM in complex surgical 
procedures







– In liver transplant patients, what are 
baseline coagulation profiles – using 
basic ROTEM measurements – to 
expect based on certain transplant 
procedure etiologies?
• Hypothesis
– More coagulopathy – increased 
ROTEM clotting time, etc. – will be 
observed in patients with whole liver
transplant etiologies (e.g. alcoholic 
cirrhosis) than a focal hepatocellular 
carcinoma transplant etiology
Brief review of methods
Data: ROTEM coagulation measurements at Jefferson have been acquired 
from approximately 400 liver transplant patients since 2013
PICO
Population - liver transplant patients at Jefferson, 2013-present
Intervention - ROTEM data acquired during transplant procedure
Comparator - patient groups based on hepatocellular carcinoma vs. 
whole hepatocellular pathology etiology
Other –
– Outcome measures (complete data in 221 patients) –
• ROTEM coagulation measurements e.g. clotting time, clot formation time
• MELD scores (uses serum bilirubin, INR, serum creatinine from EPIC)
– Analysis – paired t-test comparing patient groups, correlations run 
comparing continuous measurement variables
Prior to reporting coagulation profiles of patients 
from our database, we wanted to test levels of 
correspondence between our ROTEM 
measurements with a proven indicator of risk…
MELD scores in liver transplants 
• MELD score – Model for End-
stage Liver Disease -- is 
predictive of post-surgery 
mortality
• Computed from EPIC chart 
review of patients in database 





• These values will be included 
in patient coagulation profiles
Figure 1 of Saab et al. (2003), 




• Question: Do patient MELD scores correlate 
with baseline ROTEM clotting times?
Results, HCC vs. non-HCC
For both ROTEM CT scores and MELD scores, 
the non-cancer patient group had values 
trending in the direction suggesting more 
coagulopathy











HCC 75 813.6 507.4 12.8 6.1
Other 146 944.0 495.4 23.7 9.8
Obstacles
• Data retention:
– 400 patients in total database
– 283 have a baseline NATEM measurement (71%)
– 221 have baseline NATEM + MELD score (55% of grand 
total)
• Our initial hypothesis comparison groups –
hepatocellular carcinoma (N=87)* vs. non-cancer 
(N=134)* – suffer from unbalanced sample sizes
* - Distinct patients with baseline natem values and adjusted MELD scores
Conclusions
• From this project:
– Further analysis is needed to 
investigate coagulopathy measures in 
HCC compared to other transplants
• Overall, our overarching aim is to 
provide more resources for ROTEM 
users to increase overall utilization 
in ORs
• Providing baseline profiles for liver 
transplant patients has utility even 
without hypothesis testing
Future directions
• Outlier handling to reduce population 
variance
– Is this methodologically sound while studying 
liver pathology?
• Assess coagulation measures across other 
demographic variables
– Age, Sex, Race/Ethnicity, other disease processes
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